Lead Sponsor

Pulmocide Ltd

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Received an allogeneic or autologous hematopoietic stem cell transplant (HSCT) using any conditioning regimen
•Experienced new onset of at least one of the following respiratory symptoms ≤5 days before study Day 1:
•Nasal congestion or stuffiness, runny nose (rhinorrhoea), cough, or sore throat OR Worsening of at least one of those symptoms, if symptoms are chronic OR Wheezing, sputum production, pleuritic chest pain, increased respiratory rate, signs on chest auscultation, hypoxia, increased supplemental oxygen requirement or new infiltrates on chest X-ray/CT
•A positive RSV diagnostic test
•Provided written informed consent

•Is intubated and requires invasive ventilation
•Has received any investigational RSV vaccine after HSCT, or has received any monoclonal anti-RSV antibodies within 4 months or 5 half-lives before participation
•Treatment with intravenous ribavirin
•Positive for test for influenza or parainfluenza
•Significant untreated bacteraemia or fungaemia
•Significant untreated bacterial, fungal, or viral pneumonia
•Precluded from participating as a result of treatment with another investigational drug or participation in another clinical trial
•Other disease or condition which would preclude the subject's participation in a clinical trial
•Is receiving an antiretroviral protease inhibitor
•Has chronic, active hepatitis infection
•Known alcohol or drug abuse

Related studies

NCT07220109 · Respiratory Syncytial Virus Infections

NCT07092865 · Respiratory Syncytial Virus Infections

NCT07239583 · Respiratory Syncytial Virus Infection, Respiratory Syncytial Virus Infections

NCT06534892 · Respiratory Syncytial Virus Infections

NCT06593210 · Vaccine Response Impaired, Respiratory Syncytial Virus Infections, and more

Anti-viral Effect of PC786 on RSV Infection on HSCT Recipients